These findings are consistent with a previous study that found higher plasmablast counts and lower total CD4+ T, total CD8+ T, CD4+ Tem, CD8+ Tem, Treg, NK, and DC counts in immune cell populations sampled on post-infection days 0–14 in patients with COVID-19 who experienced persisting symptoms at days 91–180 after infection (29). The gene discussed is CD8A; the disease is COVID-19.